» Articles » PMID: 33780511

Brief Report: Lymph Node Morphology in Stage II Colorectal Cancer

Overview
Journal PLoS One
Date 2021 Mar 29
PMID 33780511
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Colorectal cancer is one of the leading causes of cancer-associated morbidity and mortality worldwide. The local anti-tumour immune response is particularly important for patients with stage II where the tumour-draining lymph nodes have not yet succumbed to tumour spread. The lymph nodes allow for the expansion and release of B cell compartments such as primary follicles and germinal centres. A variation in this anti-tumour immune response may influence the observed clinical heterogeneity in stage II patients.

Aim: The aim of this study was to explore tumour-draining lymph node histomorphological changes and tumour pathological risk factors including the immunomodulatory microRNA-21 (miR-21) in a small cohort of stage II CRC.

Methods: A total of 23 stage II colorectal cancer patients were included. Tumour and normal mucosa samples were analysed for miR-21 expression levels and B-cell compartments were quantified from Haematoxylin and Eosin slides of lymph nodes. These measures were compared to clinicopathological risk factors such as perforation, bowel obstruction, T4 stage and high-grade.

Results: We observed greater Follicle density in patients with a lower tumour T stage and higher germinal centre density in patients with higher pre-operative carcinoembryonic antigen levels. Trends were also detected between tumours with deficiency in mismatch repair proteins, lymphatic invasion and both the density and size of B-cell compartments. Lastly, elevated tumour miR-21 was associated with decreased Follicle and germinal centre size.

Conclusion: Variation in B-cell compartments of tumour-draining lymph nodes is associated with clinicopathological risk factors in stage II CRC patients.

Citing Articles

Lymph node dissection does not affect the survival of patients with tumor node metastasis stages I and II colorectal cancer.

He F, Qu S, Yuan Y, Qian K World J Gastrointest Surg. 2024; 16(8):2503-2510.

PMID: 39220053 PMC: 11362951. DOI: 10.4240/wjgs.v16.i8.2503.


The risk factors of low anterior resection syndrome after colorectal cancer surgery: A retrospective study of 566 patients in a single institution in China.

Ri H, Kang H, Xu Z, Kim K, Ren Y, Gong Z Front Surg. 2022; 9:990702.

PMID: 36439535 PMC: 9683037. DOI: 10.3389/fsurg.2022.990702.

References
1.
El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View

2.
Sheedy F, Palsson-McDermott E, Hennessy E, Martin C, OLeary J, Ruan Q . Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2009; 11(2):141-7. DOI: 10.1038/ni.1828. View

3.
Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker A . Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer. 2016; 122(21):3277-3287. PMC: 5073024. DOI: 10.1002/cncr.30181. View

4.
Benson 3rd A, Hamilton S . Path toward prognostication and prediction: an evolving matrix. J Clin Oncol. 2011; 29(35):4599-601. DOI: 10.1200/JCO.2011.37.8646. View

5.
Engstrom P, Arnoletti J, Benson 3rd A, Chen Y, Choti M, Cooper H . NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009; 7(8):778-831. DOI: 10.6004/jnccn.2009.0056. View